Next-Generation Degrader Antibody Conjugates

• Our next-generation Degrader Antibody Conjugates (DAC) are designed to improve safety and efficacy through advanced antibody and linker engineering
• DACs combine the tissue selectivity of antibody-mediated delivery with the well-validated catalytic mechanism of targeted protein degradation
• DACs offer opportunities to expand beyond conventional cytotoxic ADC payloads

Speakers:

Maysoun Shomali

Executive Director

Orum Therapeutics, Inc.